Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Introduction: Aim of the present study was to evaluate the real-world impact of once-weekly (OW) subcutaneous semaglutide on different end-points indicative of metabolic control, cardiovascular risk factors, and beta-cell function in type 2 diabetes (T2D). Methods: This was a retrospective, observational study conducted in 5 diabetes clinics in Italy. Changes in HbA1c, fasting blood glucose (FBG), body weight, blood pressure, lipid profile, renal function, and beta-cell function (HOMA-B) during 12 months were evaluated. Results: Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years). After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg. Systolic blood pressure, total and LDL-cholesterol significantly improved. Benefits were sustained at 12 months. Renal safety was documented. HOMA-B increased from 40.2% to 57.8% after 6 months (p<0.0001). Discussion: The study highlighted benefits of semaglutide on metabolic control, multiple CV risk factors, and renal safety in the real-world. Semaglutide seems to be an advisable option for preservation of β-cell function and early evidence suggests it might have a role in modifying insulin resistance (HOMA-IR), the pathogenetic basis of prediabetes and T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“Semaglutide is the most recent available GLP-1RA; it has a sequence homology of 94% compared to human GLP-1 and is the first analogue available in both injectable and oral formulation (15).”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“OW semaglutide is indicated in subjects with uncontrolled type 2 diabetes as a monotherapy when the use of metformin is contraindicated, or as an add-on therapy with other glucoselowering drugs, including insulin (18, 19); furthermore, based on the most recent guidelines, it can be considered for use as a first-line t…”
BackgroundNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Blonde, L., Khunti, K., Harris, S. B., Meizinger, C., & Skolnik, N. S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0805-y · Cited by 714 · cited 1×
“As known, real-world studies allow to assess whether the results of experimental studies can be reproduced in broader samples of patients managed under routine clinical practice (24).”
BackgroundAhmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · cited 2×
“GLP-1 is an intestinal hormone which stimulates insulin secretion and inhibits pancreas glucagon secretion at carbohydrates intake (4).”
BackgroundGutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
Insulin Resistance and Cardiovascular Disease1
McFarlane, S. I., Banerji, M., & Sowers, J. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7202 · Cited by 501
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406 · cited 1×
“In clinical studies, GLP-1RAs exerted a positive effect on glycated hemoglobin (HbA1c), body weight, and cardiovascular risk factors (plasma lipids, systolic blood pressure and inflammation) (10, 11).”
BackgroundSelf-citationInsulin Resistance and Cardiovascular Disease
McFarlane, S. I. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.713 · Cited by 377
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Aroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.12.001 · Cited by 296 · cited 1×
“) semaglutide was evaluated in over 7000 patients in six global phase IIIa trials and in nearly 3000 patients in four phase IIIb trials (SUSTAIN program) (21).”
BackgroundAnti-diabetic drugs and weight loss in patients with type 2 diabetes
Lazzaroni, E., Ben Nasr, M., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105782 · Cited by 182
Self-citationSchernthaner, G., Shehadeh, N., Ametov, A. S., Bazarova, A. V., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalić, N. M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01154-w · Cited by 164 · cited 1×
“It is known that T2D is a chronic degenerative disease characterized by high risk of complications and an increasing social, economic and health burden worldwide (52, 53); on the other hand, GLP-1 therapy is recognized as one of the key strategies to overcome clinical inertia in cardiorenal protection of T2DM patients…”
BackgroundGLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144 · cited 1×
“Renal parameters (eGFR and ACR) were unchanged after 12 months of treatment, confirming the renal safety of GLP1-RAs which were demonstrated to prevent the onset of macroalbuminuria and slow the decline of eGFR (39).”
BackgroundPerreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P. H., Wallenstein, S. O. R., & le Roux, C. W. (2022) · Diabetes Care · doi:10.2337/dc21-1785 · Cited by 87 · cited 1×
“There is limited current evidence to establish whether HOMA-IR amelioration with GLP-1 is an independent outcome or a secondary result from weight loss and body recomposition (50, 51).”
BackgroundFonseca, V. A., Capehorn, M. S., Garg, S. K., Jódar Gimeno, E., Hansen, O. H., Holst, A. G., Nayak, G., & Seufert, J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02685 · Cited by 63 · cited 1×
“There is limited current evidence to establish whether HOMA-IR amelioration with GLP-1 is an independent outcome or a secondary result from weight loss and body recomposition (50, 51).”
BackgroundRajamand Ekberg, N., Bodholdt, U., Catarig, A.-M., Catrina, S.-B., Grau, K., Holmberg, C. N., Klanger, B., & Knudsen, S. T. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2021.06.008 · Cited by 63
Wu, S., Gao, L., Cipriani, A., Huang, Y., Yang, Z., Yang, J., Yu, S., Zhang, Y., Chai, S., Zhang, Z., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13613 · Cited by 48 · cited 1×
“These results are in line with a recent network meta-analysis documenting that incretin-based therapies not only support an increase in HOMA-B, but also achieve a reduction in HOMA-IR in comparison with placebo; although GRADE scores indicate low to moderate quality for most of these comparisons, incretin-based therap…”
ResultBerra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 48
Self-citationJain, A. B., Kanters, S., Khurana, R., Kissock, J., Severin, N., & Stafford, S. G. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00984-x · Cited by 47
Brown, R. E., Bech, P. G., & Aronson, R. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14117 · Cited by 42
Lingvay, I., Kirk, A. R., Lophaven, S., Wolden, M. L., & Shubrook, J. H. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01010-4 · Cited by 41
Italian guidelines for the treatment of type 2 diabetes
Mannucci, E., Candido, R., Monache, L. D., Gallo, M., Giaccari, A., Masini, M. L., Mazzone, A., Medea, G., Pintaudi, B., Targher, G., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01857-4 · Cited by 36 · cited 1×
“The most recent (July 2021) Italian guidelines for the management and treatment of T2D recommend metformin, sodium-glucose co-transporter-2 inhibitors (SLGT-2is) or glucagonlike peptide-1 receptor agonists (GLP-1RAs) as first-line treatment options in patients with T2D and previous CV events (without heart failure) (1…”
BackgroundMarzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01799-2 · Cited by 34
Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort
Mirani, M., Favacchio, G., Serone, E., Lucisano, G., Rossi, M. C., & Berra, C. C. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.003 · Cited by 31
Self-citationKorsatko, S., Jensen, L., Brunner, M., Sach‐Friedl, S., Tarp, M. D., Holst, A. G., Heller, S. R., & Pieber, T. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13422 · Cited by 29
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Di Folco, U., Vallecorsa, N., Nardone, M. R., Pantano, A. L., & Tubili, C. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01936-6 · Cited by 29
Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes
Berra, C., Resi, V., Mirani, M., Folini, L., Rossi, A., Solerte, S. B., & Fiorina, P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104996 · Cited by 27
Self-citationOn behalf of the NN2211-4118 Study Group, Lapolla, A., Berra, C., Boemi, M., Bossi, A. C., Candido, R., Di Cianni, G., Frontoni, S., Genovese, S., Ponzani, P., et al. (2018) · Advances in Therapy · doi:10.1007/s12325-017-0652-2 · Cited by 26
Self-citationHansen, K. B., Svendstrup, M., Lund, A., Knop, F. K., Vilsbøll, T., & Vestergaard, H. (2021) · Diabetic Medicine · doi:10.1111/dme.14655 · Cited by 23
Dalmazi, G. D., Coluzzi, S., BALDASSARRE, M. P. A., Ghit, A., Graziano, G., Rossi, M. C., Ciappini, B., Milo, M., Carrieri, F., Nicolucci, A., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892702 · Cited by 22
Self-citationDi Loreto, C., Minarelli, V., Nasini, G., Norgiolini, R., & Del Sindaco, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01218-y · Cited by 21
Visaria, J., Uzoigwe, C., Swift, C., Dang-Tan, T., Paprocki, Y., & Willey, V. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.03.003 · Cited by 20
Safety of injectable semaglutide for type 2 diabetes
Peter, R., & Bain, S. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1772230 · Cited by 17 · cited 1×
“OW semaglutide is currently recognized as the most powerful molecule within the GLP-1RAs class (22).”
BackgroundTime in suboptimal glycemic control over 10 years for patients newly diagnosed with type 2 diabetes
An, J., Nichols, G. A., Qian, L., Harrison, T. N., Li, Z., Munis, M. A., Wei, R. X., Weiss, T., Rajpathak, S. N., & Reynolds, K. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107607 · Cited by 9 · cited 1×
“In spite of advances occurred in type 2 diabetes (T2D) therapy, achieving glycated haemoglobin (HbA1c) targets still represents a challenge for many patients (1).”
BackgroundExpanding the concept of ‘Clinical Inertia’ in diabetes
Mohan, V. (2018) · Journal of Diabetology · doi:10.4103/jod.jod_44_18 · Cited by 8 · cited 1×
“It is known that T2D is a chronic degenerative disease characterized by high risk of complications and an increasing social, economic and health burden worldwide (52, 53); on the other hand, GLP-1 therapy is recognized as one of the key strategies to overcome clinical inertia in cardiorenal protection of T2DM patients…”
BackgroundSemaglutide provides superior glycemic control across SUSTAIN 1–5 clinical trials
Ahmann, A., Chow, F. C. C., Fonseca, V. A., Roopa, M., Thomsen, H., Thielke, D., Petrie, J., & Mamede, M. (2018) · International Journal of Nutrology · doi:10.1055/s-0038-1675019 · Cited by 7
Basile, G. (2022) · The Journal of AMD · doi:10.36171/jamd22.25.2.5 · Cited by 3
Research works printed but not linked: 2
- Di Folco, 2022, Effects of semagltide on cardiovascular risk factor and eating behaviours in type 2 diabetes, Acta Diabetol, 59, 10.1007/s00592-022-01936-6 · DOI · Paper page
- Di Loreto, 2022, Effectiveness in real world of once weekly semaglutide in people with type 2 diabetes: Glucagon-like peptide receptor agonist naive or switchers from other glucagon-like peptide receptor agonists: Results from a retrospective observational study in umbria, Diabetes Ther, 13, 10.1007/s13300-022-01218-y · DOI · Paper page
Cited by
Singh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
“C 91.13 vs. 81.88 mg/ dl, p = 0.0002; TC 167.07 vs. 155.61 mg/dl; p < 0.0001) [54].”
Influential
Metadata
- Authors
- Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., Graziano, G., Lunati, M. E., Solerte, S. B., & Fiorina, P.
- Affiliations
- MultiMedica (IT)
- Center for Outcomes Research and Clinical Epidemiology (IT)
- IRCCS Humanitas Research Hospital (IT)
- Ospedale di Circolo e Fondazione Macchi (IT)
- ASST Fatebenefratelli Sacco (IT)
- University of Pavia (IT)
- University of Milan (IT)
- Corresponding author
- Berra, Cesare C.
- Rossi, Maria Chiara
- ORCID
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-18
- Volume
- 13
- Pages
- 1099451-1099451
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC9889982
- OpenAlex
- W4317107805
- Semantic Scholar
- 224562d58fbca460fe2bbab5da22ff6de198fdf5
- Cited by
- 28
- References
- 49
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 7 · 2023: 5
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, type 2 diabetes, GLP-1 receptor agonists, glycemic control, HbA1c, fasting blood glucose, weight loss, blood pressure, lipid profile, renal safety, beta-cell function, HOMA-β, insulin resistance, cardiovascular risk factors, real-world effectiveness
- MeSH terms
- Semaglutide, Aged, Body Weight, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
